Canaccord Reiterates $0.00 Price Target On Medmen

Medmen Enterprises’ (CSE: MMEN) reported their fiscal third quarter 2021 financial results on May 11th after market close. The company reported revenue of $32.03 million, a profit margin of 41.6%, and an operating margin rate of (120.9%).

Much to our surprise, Medmen has four analysts covering the company, with a weighted 12-month price target of $0.12. Roth Capital is crowned with having the street high, with a price target of $0.20, while Canaccord sits firmly at the low with a solid $0.00 price target. Out of the four analysts, one has a hold rating, two have sell ratings and another has a strong sell rating.

In Canaccord’s note, their analyst Matt Bottomley reiterates his sell rating and $0 price target, calling Medmen’s quarter a “fairly stagnant quarter,” with Medmen’s numbers missing Canaccord’s estimates. Bottomley adds, “With the company taking a step back towards profitability and a cash balance that remains razor-thin compared to its current liabilities and longer-term debt obligations, we reiterate our SELL rating and C$0.00 PT for MMEN.”

Below you can see how Medmen’s earnings came in compared to Canaccord Genuity’s estimates. Although the company missed expectations, that is without discounting its discountinued NY operations, which when adjusted for, Medmen’s revenue would be up a modest 3.8% quarter over quarter. Bottomley notes that even after the adjustment, things don’t look to be good.

In their core market, California, they only saw same store sales up 2.2% because of COVID headwinds combined with seasonality. Medmen reported a lower gross margin of only 42%, which is down from 53% the quarter prior, while SG&A ballooned 19% due to litigation costs.

Below you can see Canaccord’s revised 2021 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

Jushi Holdings: Three Analysts Initiate Coverage Over Span Of One Week

After two consecutive C$30 million raises, Jushi Holdings (CSE: JUSH) has received three new analyst...

Thursday, January 14, 2021, 11:49:00 AM

Ascend Wellness Takes MedMen To Court, Seeks To Enforce Investment Agreement

It seems Ascend Wellness Holdings, Inc. (CSE: AAWH.U) is not going to take the termination...

Friday, January 14, 2022, 10:14:00 AM

Ayr Wellness: Canaccord Reiterates Ratings After Quarterly Results

On August 16, Ayr Wellness (CSE: AYR.a) reported their second quarter financial results. The company...

Thursday, August 26, 2021, 10:24:00 AM

Medmen Posts Q4 Loss Of $46.2 Million

Medmen Enterprises (CSE: MMEN) last night reminded investors why Canaccord Genuity had a long standing...

Friday, September 24, 2021, 07:29:00 AM

SSR Mining Sees BMO Lift Price Target To US$29 Per Share

On Tuesday, SSR Mining (TSX: SSRM) reported its first quarter financial results for 2022. The...

Friday, May 6, 2022, 04:32:00 PM